Tags

Type your tag names separated by a space and hit enter

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial.
Ann Intern Med. 2011 Aug 16; 155(4):217-25.AIM

Abstract

BACKGROUND

Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza.

OBJECTIVE

To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza.

DESIGN

Prospective, nonblinded, randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00935194)

SETTING

Eleven hospitals from 4 provinces in China.

PATIENTS

410 persons [corrected] aged 15 to 69 [corrected] years with laboratory-confirmed H1N1 influenza.

INTERVENTION

Oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; or no intervention (control). Interventions and control were given for 5 days.

MEASUREMENTS

Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction.

RESULTS

Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan-yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan-yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P = 0.05) with oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P = 0.38). Two patients who received maxingshigan-yinqiaosan reported nausea and vomiting.

LIMITATIONS

Participants were young and had mild H1N1 influenza virus infection. Missing viral data precluded definitive conclusions about viral shedding.

CONCLUSION

Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection.

PRIMARY FUNDING SOURCE

Beijing Science and Technology Project and Beijing Nova Program.

Authors+Show Affiliations

Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China. cyh-birm@263.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21844547

Citation

Wang, Chen, et al. "Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan-yinqiaosan in the Treatment of H1N1 Influenza: a Randomized Trial." Annals of Internal Medicine, vol. 155, no. 4, 2011, pp. 217-25.
Wang C, Cao B, Liu QQ, et al. Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Ann Intern Med. 2011;155(4):217-25.
Wang, C., Cao, B., Liu, Q. Q., Zou, Z. Q., Liang, Z. A., Gu, L., Dong, J. P., Liang, L. R., Li, X. W., Hu, K., He, X. S., Sun, Y. H., An, Y., Yang, T., Cao, Z. X., Guo, Y. M., Wen, X. M., Wang, Y. G., Liu, Y. L., & Jiang, L. D. (2011). Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. Annals of Internal Medicine, 155(4), 217-25. https://doi.org/10.7326/0003-4819-155-4-201108160-00005
Wang C, et al. Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan-yinqiaosan in the Treatment of H1N1 Influenza: a Randomized Trial. Ann Intern Med. 2011 Aug 16;155(4):217-25. PubMed PMID: 21844547.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial. AU - Wang,Chen, AU - Cao,Bin, AU - Liu,Qing-Quan, AU - Zou,Zhi-Qiang, AU - Liang,Zong-An, AU - Gu,Li, AU - Dong,Jian-Ping, AU - Liang,Li-Rong, AU - Li,Xing-Wang, AU - Hu,Ke, AU - He,Xue-Song, AU - Sun,Yan-Hua, AU - An,Yu, AU - Yang,Ting, AU - Cao,Zhi-Xin, AU - Guo,Yan-Mei, AU - Wen,Xian-Min, AU - Wang,Yu-Guang, AU - Liu,Ya-Ling, AU - Jiang,Liang-Duo, PY - 2011/8/17/entrez PY - 2011/8/17/pubmed PY - 2011/10/7/medline SP - 217 EP - 25 JF - Annals of internal medicine JO - Ann Intern Med VL - 155 IS - 4 N2 - BACKGROUND: Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. OBJECTIVE: To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza. DESIGN: Prospective, nonblinded, randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00935194) SETTING: Eleven hospitals from 4 provinces in China. PATIENTS: 410 persons [corrected] aged 15 to 69 [corrected] years with laboratory-confirmed H1N1 influenza. INTERVENTION: Oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; or no intervention (control). Interventions and control were given for 5 days. MEASUREMENTS: Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction. RESULTS: Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan-yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan-yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P = 0.05) with oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P = 0.38). Two patients who received maxingshigan-yinqiaosan reported nausea and vomiting. LIMITATIONS: Participants were young and had mild H1N1 influenza virus infection. Missing viral data precluded definitive conclusions about viral shedding. CONCLUSION: Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection. PRIMARY FUNDING SOURCE: Beijing Science and Technology Project and Beijing Nova Program. SN - 1539-3704 UR - https://www.unboundmedicine.com/medline/citation/21844547/Oseltamivir_compared_with_the_Chinese_traditional_therapy_maxingshigan_yinqiaosan_in_the_treatment_of_H1N1_influenza:_a_randomized_trial_ DB - PRIME DP - Unbound Medicine ER -